Treatment of lung cancer patients in multidisciplinary (MDC) and serial care (SC) clinics.

• DOI: 10.1200/jco.2017.35.15_suppl.8522
• Publication Date: 2018-09-06T15:50:53Z
• Authors: Meredith Ray; Nicholas Ryan Faris; Fedoria Elaine Ru...; Matthew Smeltzer; Nana Boateng; Meghan Brooke Mea...; Courtney Foust; Bianca Jackson; Anita Patel; Carrie Fehnel; Cheryl Houston-Ha...; Raymond S Signore; Edward T Robbins; Raymond U. Osarog...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

8522 Background: MDC may improve the quality of care for complex diseases. We compared use stage-appropriate treatment lung cancer patients in a co-located to serially-referred (SC) within same healthcare system. Methods: Prospective cohort study newly-diagnosed enrolled before onset from or standard clinics (SC). Eligible pts had ECOG PS 0-2. Stage-appropriate selection was determined using National Comprehensive Cancer Network (NCCN) guidelines based on clinical stage just onset. Differences stage-based rates were calculated Chi-squared tests. Results: 162 and 317 SC. Compared serial patients, more likely black (37% v 30%) female (51% vs 48%), older (median 69 median 66) less commercially insured (36% 43%). Surgical resection frequently used early MDC: 72% 58% IA/IB (p = 0.2259); 31% IIA/B IIIA (T3N1M0) 0.0375). also trends towards higher recommended concurrent chemoradiation therapy (T4N0-1M0) (75% 53%) 0.5835), IIIB (T1-3N3, T4N2) (78% 68%), but equal (T1-3N2M0) (68% 68%). Stage IV patientss receive chemotherapy targeted SC (87% 80%) 0.3795). Conclusions: Lung model are than those usual model, despite relatively adverse demographic characteristics. Clinical trial information: NCT02123797.